Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

VYNE Therapeutics (VYNE) Operating Expenses (2016 - 2025)

VYNE Therapeutics (VYNE) has disclosed Operating Expenses for 10 consecutive years, with $7.6 million as the latest value for Q2 2025.

  • For the quarter ending Q2 2025, Operating Expenses fell 28.17% year-over-year to $7.6 million, compared with a TTM value of $29.9 million through Dec 2025, down 32.34%, and an annual FY2025 reading of $30.3 million, down 31.31% over the prior year.
  • Operating Expenses was $7.6 million for Q2 2025 at VYNE Therapeutics, down from $9.4 million in the prior quarter.
  • Across five years, Operating Expenses topped out at $22.2 million in Q2 2021 and bottomed at $6.0 million in Q1 2023.
  • Average Operating Expenses over 5 years is $10.4 million, with a median of $9.3 million recorded in 2021.
  • The sharpest move saw Operating Expenses plummeted 87.55% in 2021, then skyrocketed 108.13% in 2024.
  • Year by year, Operating Expenses stood at $9.1 million in 2021, then decreased by 12.38% to $8.0 million in 2022, then fell by 13.54% to $6.9 million in 2023, then skyrocketed by 86.07% to $12.9 million in 2024, then plummeted by 40.8% to $7.6 million in 2025.
  • Business Quant data shows Operating Expenses for VYNE at $7.6 million in Q2 2025, $9.4 million in Q1 2025, and $12.9 million in Q4 2024.